Trials / Completed
CompletedNCT00447681
Study of the Safety, Tolerability, Pharmacokinetics and Pharmcodynamics of ILV-094 in Healthy Subjects
Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetiks, and Pharmacodynamics of ILV-094 Administered Intravenously and One Dose of ILV-094 Administered Subcutaneously to Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (estimated)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This a randomized, double-blind placebo-controlled inpatient/outpatient, sequential group study of ascending single IV doses of ILV-094, an investigational drug, administered to healthy subjects. In addition, there will be one sub-cutaneous dose cohort, which will follow the 25 mg IV dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ILV-094 |
Timeline
- Start date
- 2006-12-01
- Completion
- 2007-11-01
- First posted
- 2007-03-15
- Last updated
- 2007-12-13
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00447681. Inclusion in this directory is not an endorsement.